

CONFERENCE PROGRAM

Saturday, December 2

5:00 p.m.–6:00 p.m.

Welcome and Opening Keynote

Promenades West, East and Salons I-III

The landscape of alterations in metastatic prostate cancer

Arul M. Chinnaiyan, University of Michigan, Ann Arbor, MI

6:00 p.m.–8:00 p.m.

Welcome Reception

Sunday, December 3

7:00 a.m.–8:00 a.m.

Breakfast

East Foyer, Marvin Gardens Lobby & Marvin Gardens Patio

8:00 a.m.–10:00 a.m.

Plenary Session 1: Translating Prostate Cancer Genomics

Session Chair: Mark A. Rubin, University of Bern Department for BioMedical Research, Bern, Switzerland and Weill Cornell Medicine, New York, NY

Promenades West, East and Salons I-III

Prostate cancer: DNA-based risk assessment

William B. Isaacs, Johns Hopkins Hospital, Baltimore, MD

Differential impact of RB pathway status on E2F1 reprogramming and disease progression in human prostate cancer

Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

Clinical and genomic resistance to existing and emerging therapies in prostate cancer

Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

Synthesis and evaluation of structure-activity based derivatives of ERGi-USU, a selective inhibitor for ERG-positive prostate cancer cells*

Ahmed A. Mohamed, Uniformed Services University of the Health Sciences, Bethesda, MD

Differential impact of RB status on E2F1 reprogramming in human cancer*

Christopher McNair, Thomas Jefferson University, Philadelphia, PA

10:00 a.m.–10:30 a.m.

Break

Promenade Foyer

*Short talks from proffered abstracts

CONFERENCE PROGRAM

- 10:30 a.m.–12:30 p.m.**
- Plenary Session 2: Prostate Cancer Behavior—Distinguishing the Tigers from the Kittens**
Session Chair: Himisha Beltran, Weill Cornell Medical College, New York, NY
Promenades West, East and Salons I-III
- Emerging therapeutic strategies for androgen-indifferent prostate cancer**
Himisha Beltran
- The role of imaging in helping us to discriminate clinically significant prostate cancer from insignificant disease**
Mark Emberton, University College London Hospitals, London, United Kingdom
- Title to be announced**
Felix Y. Feng, University of California San Francisco, San Francisco, CA
- Radio-resistance of PTEN-deficient prostate tumors is enhanced by treatment-induced chemokine signaling and is associated with biochemical recurrence and development of metastasis***
Chris W.D. Armstrong, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom
- Oncogenic convergence of normal human prostate epithelial cells to a small cell neuroendocrine phenotype***
Jung Wook Park, University of California Los Angeles, Los Angeles, CA
- 12:30 p.m.–2:30 p.m.**
- Lunch on Own**
- 2:30 p.m.–4:30 p.m.**
- Plenary Session 3: Roundtable on the Clinical Development of Biomarkers—Do We Need Better Biomarkers to Identify Higher-Risk, Locally Advanced Disease?**
Moderator: Lorelei A. Mucci, Harvard School of Public Health, Boston, MA
Promenades West, East and Salons I-III
- Introduction**
Lorelei A. Mucci
- Early detection of high-risk localized prostate cancer**
Scott A. Tomlins, University of Michigan Medical School, Ann Arbor, MI
- Early, highly specific risk stratification for lethal prostate cancer using a prespecified statistical model based on four Kallikrein markers in blood**
Hans G. Lilja, Memorial Sloan Kettering Cancer Center, New York, NY
- Comprehensive transcriptomic profiling challenges the robustness of prostate cancer prognostic signatures to multifocality***
Daniel H. Hovelson, University of Michigan, Ann Arbor, MI
- Whole blood assay for rapid detection of AR-v7 in metastatic castration-resistant prostate cancer: No correlation with response to androgen-axis targeting agents***
Sarah To, Monash University, Melbourne, VIC, Australia
- 4:30 p.m.–6:30 p.m.**
- Reception and Poster Session A**
Salons IV-VI and Marvin Gardens and Marvin Gardens Patio

*Short talks from proffered abstracts

Monday, December 4

7:00 a.m.–8:00 a.m.

Breakfast

East Foyer, Marvin Gardens Lobby and Marvin Gardens Patio

8:00 a.m.–10:00 a.m.

Plenary Session 4: Risk and Screening—Where Next?

Session Chair: Freddie C. Hamdy, University of Oxford, Oxford, United Kingdom

Promenades West, East and Salons I-III

Risk and appropriate screening of African-Americans for prostate cancer

Isaac J. Powell, Barbara Ann Karmanos Cancer Institute, Detroit, MI

Germline genetic testing in prostate cancer

Colin Pritchard, University of Washington, Seattle, WA

The ProtecT study and early detection: What have we learnt?

Freddie C. Hamdy

Does coffee consumption confer survival benefits among men diagnosed with prostate cancer? A large prospective analysis in the Health Professionals Follow-up Study*

Cindy Zhou, Harvard T. H. Chan School of Public Health, Boston, MA

The past, current, and future incidence rates and burden of metastatic prostate cancer in the United States*

Michael Cook, National Cancer Institute, Rockville, MD

10:00 a.m.–10:30 a.m.

Break

Promenade Foyer

10:30 a.m.–12:30 p.m.

Plenary Session 5: Novel Therapeutic Strategies and Drug Targets

Session Chair: Johann de Bono, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Promenades West, East and Salons I-III

Improving prostate cancer care through novel therapeutic strategies

Johann de Bono

Identification of synthetic lethal dependencies in CRPC

Myles A. Brown, Dana-Farber Cancer Institute, Boston, MA

Targeting oligometastatic disease in prostate cancer

Kenneth J. Pienta, Johns Hopkins University School of Medicine, Baltimore, MD

Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer* (Not CME accredited)

Nigel Brooks, CellCentric Ltd., Cambridge, United Kingdom

A highly potent novel class of P160-SRC inhibitors for the treatment of castration-resistant prostate cancer*

Salma Kaochar, Baylor College of Medicine, Houston, TX

*Short talks from proffered abstracts

CONFERENCE PROGRAM

12:30 p.m.–2:30 p.m.

Lunch and Poster Session B

Salons IV-VI and Marvin Gardens and Marvin Gardens Patio

2:30 p.m.–4:30 p.m.

Plenary Session 6: DNA Repair and Prostate Cancer

Session Chair: Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA
Promenades West, East and Salons I-III

**Multimodal tumor genomics and the microenvironment:
Annotating DNA repair and aggressive prostate cancer**

Robert G. Bristow, University Health Network Princess Margaret Hospital,
Toronto, ON, Canada

PARP inhibitor resistance in prostate cancer

Alan D. D'Andrea

Sensitivity and resistance biomarkers to PARP inhibitors in mCRPC

Joaquin Mateo, The Institute of Cancer Research and The Royal Marsden NHS
Foundation Trust, Sutton, United Kingdom

**An automated tissue staining and quantitative digital image analysis pipeline
for quantification of DNA damage repair at the single-cell level***

Beatrice Knudsen, Cedars-Sinai Medical Center, Los Angeles, CA

High-risk pathologic and genomic features of BRCA2-mutant prostate cancer*

Laura H. Porter, Monash University, Clayton, VIC, Australia

4:30 p.m.–5:30 p.m.

Hot Topics in Prostate Cancer Research: Late-Breaking Results

Session Chair: Elin Thysell, Department of Medical Biosciences, Pathology,
Umea University, Umea, Sweden
Promenades West, East and Salons I-III

**Prostate cancer neoadjuvant intensive androgen-deprivation therapy
selects for tumor foci with diverse oncogenic alterations***

Adam G. Sowalsky, National Cancer Institute, Bethesda, MD

**Stem cell-directed pan-cancer analysis reveals a human adult stem cell signature
that defines aggressive epithelial cancer subtypes***

Bryan A. Smith, University of California Los Angeles, Los Angeles, CA

Clinically relevant molecular subgroups of prostate cancer bone metastases*

Elin Thysell

**Genomic variations associated with prostate cancer in large cohort
of African American men***

Walter Rayford, The Urology Group LLC, Memphis, TN

5:30 p.m.

Evening Off

*Short talks from proffered abstracts

CONFERENCE PROGRAM

Tuesday, December 5

7:00 a.m.–8:00 a.m.

Breakfast

East Foyer, Marvin Gardens Lobby and Marvin Gardens Patio

8:00 a.m.–10:00 a.m.

Plenary Session 7: Alternate Mechanisms of Resistance

Session Chair: Wassim Abida, Memorial Sloan Kettering Cancer Center, New York, NY
Promenades West, East and Salons I-III

Lineage plasticity in antiandrogen resistance

Wassim Abida

AR is ablated: Now what? Targeting the double-negative phenotype

Peter S. Nelson, Fred Hutchinson Cancer Research Center, Seattle, WA

Phenotype plasticity: A novel mechanism of targeted therapy resistance

Mark A. Rubin, University of Bern Department for BioMedical Research, Bern, Switzerland and Weill Cornell Medicine, New York, NY

Identity fraud: Lineage plasticity as a mechanism of anti-androgen resistance and target for therapy*

Alastair Davies, Vancouver Prostate Centre, Vancouver, BC, Canada

Drug response variability between luminal and basal prostate cancer tumors*

Robert Den, Thomas Jefferson University, Philadelphia, PA

10:00 a.m.–10:30 a.m.

Break

Promenade Foyer

10:30 a.m.–12:30 p.m.

Plenary Session 8: Immunotherapy and Prostate Cancer

Session Chair: Andrea Alimonti, Institute of Oncology Research, Bellinzona, Switzerland
Promenades West, East and Salons I-III

Targeting tumor-infiltrating myeloid cells for prostate cancer therapy

Andrea Alimonti

Using genomics to unravel the immune landscape of prostate cancer

Olivier Elemento, Weill Cornell Medical College, New York, NY

Making immunotherapy work in prostate cancer

James L. Gulley, National Cancer Institute, Bethesda, MD

PSMA-specific CARTyrin T-stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model* (Not CME accredited)

Jenessa Barbara Smith, Poseida Therapeutics, San Diego, CA

12:30 p.m.–1:30 p.m.

Closing Keynote Presentation

Impressions of a new NCI Director

Norman E. Sharpless, National Cancer Institute, Bethesda, MD

1:30 p.m.

Closing Remarks

*Short talks from proffered abstracts